PharmaShots Weekly Snapshots (December 05–09, 2022)
Published: Dec 09, 2022 | Tags: Akero, Efruxifermin, Nonalcoholic Steatohepatitis, Regulatory, US, FDA, Breakthrough Therapy Designation
Published: Dec 09, 2022 | Tags: BeiGene, Phanes Therapeutics, PT199, Tislelizumab, Multiple Advanced Solid Tumors, Pharma
Published: Dec 09, 2022 | Tags: Vertex, Entrada Therapeutics, Endosomal Escape Vehicle Therapies, Myotonic Dystrophy Type 1, Pharma
Published: Dec 09, 2022 | Tags: Daiichi Sankyo, Datopotamab Deruxtecan, Dato-DXd, Metastatic Breast Cancer, Clinical Trial, P-I, TROPION-PanTumor01, SABCS, 2022
Published: Dec 09, 2022 | Tags: Guardant Health, AstraZeneca, Guardant360 CDx Blood Test, ESR1-mutated Metastatic Breast Cancer, MedTech
Published: Dec 09, 2022 | Tags: AstraZeneca, Faslodex, fulvestrant, Capivasertib, Advanced HR-Positive Breast Cancer, Clinical Trial, P-III, CAPItello-291 Trial, SABCS, 2022
Published: Dec 08, 2022 | Tags: Takeda, Qdenga, Dengue Tetravalent Vaccine, Dengue Disease, Regulatory, EC, Approval, EU
Published: Dec 08, 2022 | Tags: Roche, Replimune, RP3, RP2, Colorectal Cancer, Hepatocellular Carcinoma, Master Clinical Trial Collaboration, Supply Agreement, Pharma
Published: Dec 08, 2022 | Tags: UCB, Bimekizumab, Psoriatic Arthritis, Clinical Trial, P-III, BE OPTIMA, P-III, BE COMPLETE, Studies, The Lancet
Published: Dec 08, 2022 | Tags: Boehringer Ingelheim, Eli Lilly, Jardiance, empagliflozin, Type 2 Diabetes, P-III, DINAMO Trial, Clinical Trial, IDF, 2022
Published: Dec 08, 2022 | Tags: Novartis, Kisqali, ribociclib, Metastatic Breast Cancer, P-II (RIGHT Choice) Trial, Clinical Trial, SABCS, 2022
Published: Dec 08, 2022 | Tags: Daiichi Sankyo, AstraZeneca, Enhertu, trastuzumab deruxtecan, HER2 Positive Metastatic Breast Cancer, Clinical Trial, P-III, DESTINY-Breast03 Trial, SABCS, 2022
Ascletis Receives the US FDA’s IND Approval of ASC11 for the Treatment of COVID-19
Published: Dec 07, 2022 | Tags: Ascletis, ASC11, COVID-19, Regulatory, US, FDA, IND, Approval
Published: Dec 07, 2022 | Tags: Eli Lilly, Verzenio, abemaciclib, Early Breast Cancer, P-III (monarchE) Trial, Clinical Trial, SABCS, 2022
Published: Dec 07, 2022 | Tags: Ultromics, EchoGo Heart Failure, Preserved Ejection Fraction, Regulatory, MedTech, US, FDA, Clearance
Published: Dec 07, 2022 | Tags: AbbVie, HotSpot Therapeutics, IRF5 Program, Smart Allostery drug discovery platform, autoimmune diseases, Option to License Agreement, Pharma
Akeso Out Licenses its Ivonescimab to Summit for ~$5B
Published: Dec 07, 2022 | Tags: Akeso, Summit, Ivonescimab, AK112, SMT112, Keytruda, Non-Small Cell Lung Cancer, Out Licenses, ~$5B, Biotech
Published: Dec 07, 2022 | Tags: Equillium, Ono, Itolizumab, Acute Graft-Versus-Host Disease, alopecia areata, celiac disease, Option, Asset Purchase Agreement, Pharma
Published: Dec 06, 2022 | Tags: Tonix, Boston Children's Hospital, TNX-1500, Graft-Versus-Host Disease, Animals, Sponsored Research Agreement, Animal Health
Published: Dec 06, 2022 | Tags: Evaxion, ExpreS²ion, Cytomegalovirus Vaccine, Discovery Collaboration Agreement, Pharma
Published: Dec 06, 2022 | Tags: Ionis, Tofersen, Superoxide Dismutase 1 Amyotrophic Lateral Sclerosis, Regulatory, EMA, MAA
Published: Dec 06, 2022 | Tags: Mirati, MRTX849, adagrasib, Pembrolizumab, NSCLC, ESMO, 2022, Clinical Trial, P-II, KRYSTAL-7, P-Ib, KRYSTAL-1 Trials
Published: Dec 06, 2022 | Tags: Medtronic, Pulsed Field Ablation Catheter, Atrial Fibrillation, Clinical Trial, SPHERE Per-AF Trial
Published: Dec 06, 2022 | Tags: Incyte, Syndax, Axatilimab, Chronic Graft-Versus-Host Disease, Journal of Clinical Oncology, Clinical Trial, P-I/II Trial
Published: Dec 05, 2022 | Tags: Innovent, UNION Therapeutics, Orismilast, IBI353, Atopic Dermatitis, Psoriasis, Clinical Trial, P-I Study
Published: Dec 05, 2022 | Tags: MaxCyte, Curamys, Cell, Gene Therapies, Rare Intractable Diseases, Strategic Platform License
Published: Dec 05, 2022 | Tags: Mayne Pharma, TherapeuticsMD, Imvexxy, Bijuva, BocaGreenMD, vitaMedMD, Annovera, License Agreement, Pharma
Immunocore Entered into an Agreement with Gadeta to Develop Gamma Delta TCR ImmTAC for Solid Tumors
Published: Dec 05, 2022 | Tags: Immunocore, Gadeta, Gamma Delta TCR ImmTAC, Solid Tumors, Biotech
Published: Dec 05, 2022 | Tags: Incyte, CMS, Ruxolitinib Cream, immune-mediated dermatologic conditions, Greater China, Southeast Asia, Pharma
Published: Dec 05, 2022 | Tags: AnaptysBio, GSK, Jemperli, dostarlimab, Endometrial Cancer, Clinical Trial, P-III Trial
Related Post: PharmaShots Weekly Snapshots (November 28 – December 02, 2022)
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.